Halvorsen YD, et al. - In this randomized, double-blind, active-controlled clinical trial, researchers compared the relative safety and efficacy of bexagliflozin and sitagliptin in treating adults with type 2 diabetes as adjuncts to metformin. For this investigation, 386 candidates were randomized to receive bexagliflozin (20 mg) or sitagliptin (100 mg) in addition to their existing doses of metformin. Investigators found that the decrease in HbA1c caused by daily bexagliflozin administration over a 24-week period was not lower than that caused by daily sitagliptin administration. Bexagliflozin provided additional benefits in terms of magnitude that were clinically significant and statistically significant. The incidence of adverse events in the two arms was similar. Nasopharyngitis, urinary tract infection, hypoglycemia, and influenza were the most commonly reported treatment-emergent adverse events.